Collaboration for rare disease drug discovery research

F1000Research

Volumn 3, Issue , 2014, Pages

  Litterman, Nadia K ^a   Rhee, Michele ^b   Swinney, David C ^c   Ekins, Sean ^a,d,e,f,g  

^a Collaborative Drug Discovery Inc ^*  (United States)

^b National Brain Tumor Society   (United States)

^c Institute for Rare and Neglected Diseases Drug Discovery (iRND)   (United States)

^d Collaborations in Chemistry ^*  (United States)

^e Phoenix Nest Inc   (United States)

^f Hereditary Neuropathy Foundation   (United States)

^g Hannah's Hope Fund   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADX 71441; ANTISENSE OLIGONUCLEOTIDE; ASCORBIC ACID; BACLOFEN PLUS NALTREXONE PLUS SORBITOL; ECALLANTIDE; ICATIBANT; MUSCLE RELAXANT AGENT; OLESOXIME; RG 3039; RG 7800; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG INDUSTRY; DRUG MEGADOSE; DRUG REPOSITIONING; FINANCIAL MANAGEMENT; GENE TRANSFER; GENETIC ANALYSIS; GIANT AXONAL NEUROPATHY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; INFORMATION DISSEMINATION; INFORMATION TECHNOLOGY; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PATIENT ADVOCACY; SANFILIPPO SYNDROME; SOCIAL NETWORK; SPINAL MUSCULAR ATROPHY; TREATMENT PLANNING;

EID: 84923331367     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.5564.1     Document Type: Article

References (99)

1. Melnikova I: Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012;11(4):267-8. 22460117 10.1038/nrd3654
2. Field MJ Boat TF: Rare Diseases and Orphan Products: Accelerating Research and Development. Washington DC: The National Academics Press.2011. Reference Source
3. Swinney DC Xia S: The discovery of medicines for rare diseases. Future Med Chem. 2014;6(9):987-1002. 25068983 10.4155/fmc.14.65
4. DiVincenzo C Elzinga CD Medeiros AC: The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy. Mol Genet Genomic Med. 2014. In press. 10.1002/mgg3.106
5. Grabowski P Briest F Baum RP: Vandetanib therapy in medullary thyroid cancer. Drugs Today (Barc). 2012;48(11):723-33. 23170308
6. Ogawa S Takita J Sanada M: Oncogenic mutations of ALK in neuroblastoma. Cancer Sci. 2011;102(2):302-8. 21205076 10.1111/j.1349-7006.2010.01825.x
7. Paul SM Mytelka DS Dunwiddie CT: How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-14. 20168317 10.1038/nrd3078
8. Munos B: Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8(12):959-68. 19949401 10.1038/nrd2961
9. Wood J Sames L Moore A: Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. Drug Discov Today. 2013;18(21-22):1043-1051. 23968993 10.1016/j.drudis.2013.08.006
10. Miyamoto BE Kakkis ED: The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet J Rare Dis. 2011;6:49. 21733145 10.1186/1750-1172-6-49 3149566
11. Beaulieu CL Samuels ME Ekins S: A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis. 2012;7:39. 22704758 10.1186/1750-1172-7-39 3458970
12. Terry N: Health privacy is difficult but not impossible in a post-HIPAA data-driven world. Chest. 2014;146(3):835-40. 25180726 10.1378/chest.13-2909
13. Perkins JA Coltrera MD: Relational databases for rare disease study: application to vascular anomalies. Arch Otolaryngol Head Neck Surg. 2008;134(1):62-6. 18209139 10.1001/archoto.2007.12
14. Anon. Sermo. Reference Source
15. Anon. Doximity. Reference Source
16. Might M Wilsey M: The shifting model in clinical diagnostics: how next-generation sequencing and families are altering the way rare diseases are discovered, studied, and treated. Genet Med. 2014;16(10):736-7. 24651604 10.1038/gim.2014.23
17. Mnookin S: One of a kind, in The New Yorker. 2014. Reference Source
18. Rhee M Mui P Cadogan C: The role of brain tumor advocacy groups. Curr Neurol Neurosci Rep. 2014;14(4):442. 24604060 10.1007/s11910-014-0442-z
19. Sames L Moore A Arnold R: Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy. F1000Res. 2014;3:83. 24860645 10.12688/f1000research.3751.2 4023663
20. Foundation EMK: The Kauffman Index of Entrepreneurial Activity: 1996-2013.2014. Reference Source
21. Pearn J: Autosomal dominant spinal muscular atrophy: a clinical and genetic study. J Neurol Sci. 1978;38(2):263-75. 712386 10.1016/0022-510X(78)90072-2
22. Zerres K Rudnik-Schoneborn S: Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518-23. 7733848 10.1001/archneur.1995.00540290108025
23. Lefebvre S Bürglen L Reboullet S: Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155-65. 7813012 10.1016/0092-8674(95)90460-3
24. Lefebvre S Burlet P Liu Q: Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16(3):265-9. 9207792 10.1038/ng0797-265
25. Lorson CL Hahnen E Androphy EJ: A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999;96(11):6307-11. 10339583 10.1073/pnas.96.11.6307 26877
26. Edens BM Ajroud-Driss S Ma L: Molecular mechanisms and animal models of spinal muscular atrophy. Biochim Biophys Acta. 2014. 25088406 10.1016/j.bbadis.2014.07.024
27. Monani UR Coovert DD Burghes AH: Animal models of spinal muscular atrophy. Hum Mol Genet. 2000;9(16):2451-7. 11005801 10.1093/hmg/9.16.2451
28. Schmid A DiDonato CJ: Animal models of spinal muscular atrophy. J Child Neurol. 2007;22(8):1004-12. 17761656 10.1177/0883073807305667
29. Cherry JJ Kobayashi DT Lynes MM: Assays for the identification and prioritization of drug candidates for spinal muscular atrophy. Assay Drug Dev Technol. 2014;12(6):315-41. 25147906 10.1089/adt.2014.587 4142828
30. Hua Y Sahashi K Rigo F: Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 2011;478(7367):123-6. 21979052 10.1038/nature10485 3191865
31. Lutz CM Kariya S Patruni S: Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest. 2011;121(8):3029-41. 21785219 10.1172/JCI57291 3148744
32. Naryshkin NA Weetall M Dakka A: Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345(6197):688-93. 25104390 10.1126/science.1250127
33. Passini MA Bu J Richards AM: Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011;3(72):72ra18. 21368223 10.1126/scitranslmed.3001777 3140425
34. Gogliotti RG Cardona H Singh J: The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet. 2013;22(20):4084-101. 23736298 10.1093/hmg/ddt258 3781638
35. Van Meerbeke JP Gibbs RM Plasterer HL: The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum Mol Genet. 2013;22(20):4074-83. 23727836 10.1093/hmg/ddt257 3781637
36. Benkhelifa-Ziyyat S Besse A Roda M: Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther. 2013;21(2):282-90. 23295949 10.1038/mt.2012.261 3594018
37. Passini MA Bu J Richards AM: Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther. 2014;25(7):619-30. 24617515 10.1089/hum.2014.011
38. Garde D: Isis gears up for Phase III with Biogen-partnered antisense drug.2014. Reference Source
39. Anon. SMA Foundation. Reference Source
40. Anon. CureSMA. Reference Source
41. Miller LJ Saporta AS Sottile SL: Strategy for genetic testing in Charcot-Marie-disease. Acta Myol. 2011;30(2):109-16. 22106713 3235845
42. Rangaraju S Verrier JD Madorsky I: Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice. J Neurosci. 2010;30(34):11388-97. 20739560 10.1523/JNEUROSCI.1356-10.2010 3478092
43. Naef R Suter U: Many facets of the peripheral myelin protein PMP22 in myelination and disease. Micros Res Tech. 1998;41(5):359-371. 9672419
44. Kaya F Belin S Bourgeois P: Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord. 2007;17(3):248-53. 17303424 10.1016/j.nmd.2006.12.008
45. Jang SW Lopez-Anido C MacArthur R: Identification of drug modulators targeting gene-dosage disease CMT1A. ACS Chem Biol. 2012;7(7):1205-13. 22530759 10.1021/cb300048d 3401360
46. Ainsworth C: Networking for new drugs. Nat Med. 2011;17(10):1166-8. 21988973 10.1038/nm1011-1166
47. Attarian S: A phase II randomized, placebo-controlled multicenter clinical trial of three doses of PXT3003 in 80 adult patients with CMT1A treated for 1 year. J Peripher Nerv Syst. 2013;8:197-198.
48. Hay M Thomas DW Craighead JL: Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51. 24406927 10.1038/nbt.2786
49. Anon. Addex press release.2014. Reference Source
50. Fledrich R Stassart RM Klink A: Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nat Med. 2014;20(9):1055-61. 25150498 10.1038/nm.3664
51. Anon. Hereditary Neuropathy Foundation. Reference Source
52. Anon. Charcot-Marie-Tooth Association. Reference Source
53. Lewis RA McDermott MP Herrmann DN: High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol. 2013;70(8):981-7. 23797954 10.1001/jamaneurol.2013.3178 3752369
54. Verhamme C de Haan RJ Vermeulen M: Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med. 2009;7:70. 19909499 10.1186/1741-7015-7-70 2784478
55. Yang Y Allen E Ding J: Giant axonal neuropathy. Cell Mol Life Sci. 2007;64(5):601-9. 17256086 10.1007/s00018-007-6396-4
56. Yiu EM Ryan MM: Genetic axonal neuropathies and neuronopathies of pre-natal and infantile onset. J Peripher Nerv Syst. 2012;17(3):285-300. 22971091 10.1111/j.1529-8027.2012.00412.x
57. Bomont P Cavalier L Blondeau F: The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet. 2000;26(3):370-4. 11062483 10.1038/81701
58. Fabrizi GM Cavallaro T Angiari C: Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton. Brain. 2007;130(Pt 2):394-403. 17052987 10.1093/brain/awl284
59. Mahammad S Murthy SN Didonna A: Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation. J Clin Invest. 2013;123(5):1964-75. 23585478 10.1172/JCI66387 3635735
60. Anon. Hannah's Hope Fund. Reference Source
61. Vandendriessche T Thorrez L Acosta-Sanchez A: Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost. 2007;5(1):16-24. 17002653 10.1111/j.1538-7836.2006.02220.x
62. Valstar MJ Ruijter GJ van Diggelen OP: Sanfilippo syndrome: a mini-review. J Inherit Metab Dis. 2008;31(2):240-52. 18392742 10.1007/s10545-008-0838-5
63. Druker BJ Talpaz M Resta DJ: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-7. 11287972 10.1056/NEJM200104053441401
64. Druker BJ Tamura S Buchdunger E: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-6. 8616716 10.1038/nm0596-561
65. Peng B Dutreix C Mehring G: Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 2004;44(2):158-62. 14747424 10.1177/0091270003262101
66. Buchdunger E Cioffi CL Law N: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295(1):139-45. 10991971
67. Iqbal N Iqbal N: Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027. 24963404 10.1155/2014/357027 4055302
68. Omberg L Ellrott K Yuan Y: Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat Genet. 2013;45(10):1121-6. 24071850 10.1038/ng.2761 3950337
69. Ekins S Hupcey MAZ Williams AJ: Collaborative computational technologies for biomedical research. Hoboken, NJ: Wiley.2011. 10.1002/9781118026038
70. Ekins S Hohman M Bunin BA: Pioneering use of the cloud for development of the collaborative drug discovery (cdd) database in Collaborative Computational Technologies for Biomedical Research S. Ekins, M.A.Z. Hupcey, and A.J. Williams, Editors. Wiley and Sons: Hoboken.2011.
71. Bunin BA Ekins S: Alternative business models for drug discovery. Drug Disc Today. 2011;16(15-16):643-645. 21745585 10.1016/j.drudis.2011.06.012
72. Hohman M Gregory K Chibale K: Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Disc Today. 2009;14(5-6):261-270. 19231313 10.1016/j.drudis.2008.11.015
73. Ekins S Bunin BA: The Collaborative Drug Discovery (CDD) database. Methods Mol Biol. 2013;993:139-54. 23568469 10.1007/978-1-62703-342-8_10
74. Ekins S Williams AJ Krasowski MD: In silico repositioning of approved drugs for rare and neglected diseases. Drug Disc Today. 2011;16(7-8):298-310. 21376136 10.1016/j.drudis.2011.02.016
75. Southan C Williams AJ Ekins S: Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates. Drug Disc Today. 2013;18(1-2):58-70. 23159359 10.1016/j.drudis.2012.11.005
76. Litterman NK Lipinski CA Bunin BA: Computational Prediction and Validation of an Expert's Evaluation of Chemical Probes. Submitted,2014. 10.3410/f.718883497.793500656
77. Xu K Cote TR: Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief Bioinform. 2011;12(4):341-5. 21357612 10.1093/bib/bbr006
78. Dudley JT Sirota M Shenoy M: Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011;3(96):96ra76. 21849664 10.1126/scitranslmed.3002648 3479650
79. Bhinder B Djaballah H: Drug discovery and repurposing at Memorial Sloan Kettering Cancer Center: chemical biology drives translational medicine. ACS Chem Biol. 2014;9(7):1394-7. 25033723 10.1021/cb500479z
80. Ekins S Clark AM Williams AJ: Open Drug Discovery Teams: A Chemistry Mobile App for Collaboration. Mol Inform. 2012;31(8):585-597. 23198003 10.1002/minf.201200034 3503260
81. Ekins S Clark AM: Open Drug Discovery Teams.2012. Reference Source
82. Ekins S Clark AM Swamidass SJ: Bigger data, collaborative tools and the future of predictive drug discovery. J Comput Aided Mol Des. 2014;28(10):997-1008. 24943138 10.1007/s10822-014-9762-y
83. Beaulieu CL Samuels ME Ekins S: A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis. 2012;7:39. 22704758 10.1186/1750-1172-7-39 3458970
84. Ekins S Nikolsky Y Bugrim A: Pathway mapping tools for analysis of high content data. Methods Mol Biol. 2007;356:319-50. 16988414 10.1385/1-59745-217-3:319
85. Hemperly SE Agarwal NS Xu YY: Recent advances in the management of hereditary angioedema. J Am Osteopath Assoc. 2013;113(7):546-55. 23843378 10.7556/jaoa.2013.006
86. Cicardi M Igarashi T Kim MS: Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema. J Clin Invest. 1987;80(6):1640-3. 2890659 10.1172/JCI113252 442434
87. Kaplan AP Joseph K: Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol. 2014;121:41-89. 24388213 10.1016/B978-0-12-800100-4.00002-7
88. Altman KA Naimi DR: Hereditary angioedema: a brief review of new developments. Curr Med Res Opin. 2014;30(5):923-30. 24432781 10.1185/03007995.2013.879441
89. Lehmann A: Ecallantide (Dyax/Genzyme). Curr Opin Investig Drugs. 2006;7(3):282-90. 16555689
90. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
91. Hock FJ Wirth K Albus U: Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991;102(3):769-73. 1364851 10.1111/j.1476-5381.1991.tb12248.x 1917958
92. Wirth K Hock FJ Albus U: Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991;102(3):774-7. 1364852 10.1111/j.1476-5381.1991.tb12249.x 1917928
93. Ekins S Mestres J Testa B: In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol. 2007;152:9-20. 17549047 10.1038/sj.bjp.0707305 1978274
94. Ekins S Mestres J Testa B: In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol. 2007;152(1):21-37. 17549046 10.1038/sj.bjp.0707306 1978280
95. Ekins S Williams AJ: Finding promiscuous old drugs for new uses. Pharm Res. 2011;28(8):1786-1791. 21607776 10.1007/s11095-011-0486-6
96. Blatt J Farag S Corey SJ: Expanding the scope of drug repurposing in pediatrics: The Children's Pharmacy Collaborative™. Drug Discov Today. 2014. 25149597 10.1016/j.drudis.2014.08.003
97. Murrey DA Naughton BJ Duncan FJ: Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum Gene Ther Clin Dev. 2014;25(2):72-84. 24720466 10.1089/humc.2013.208 4124586
98. Feldhammer M Durand S Pshezhetsky AV: Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C. PLoS One. 2009;4(10):e7434. 19823584 10.1371/journal.pone.0007434 2757673
99. Anon. 1R41NS089061-01. Reference Source